{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T23:52:02Z","timestamp":1777420322290,"version":"3.51.4"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,7,14]],"date-time":"2022-07-14T00:00:00Z","timestamp":1657756800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,7,14]],"date-time":"2022-07-14T00:00:00Z","timestamp":1657756800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>A high baseline hepatitis B virus (HBV) load has always been listed as an exclusion criterion for programmed cell death-1 (PD-1) inhibitor-associated therapy in clinical trials, as the interaction between HBV load and anti-PD-1\/PD-L1 therapy with anti HBV therapy remains controversial.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>We retrospectively enrolled 70 unresectable HCC patients who were seropositive for HBsAg and accepted tenofovir alafenamide fumarate (TAF) therapy before anti-PD-1 in combination with an antiangiogenic treatment. Patients were divided into a low HBV DNA group (\u2264\u20092000\u00a0IU\/ml) and a high HBV DNA group (&gt;\u20092000\u00a0IU\/ml) according to the baseline HBV DNA levels. Tumour response and progression-free survival (PFS) were compared, and univariate and multivariate Cox analyses were performed to identify potential risk factors for PFS. The incidences of HBV reactivation and HBV-associated hepatitis were also recorded.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>48 patients were assigned to the low group and the remaining 22 patients were assigned to the high group. The objective response rates (ORRs), disease control rates (DCRs), and PFS between the two groups showed no significant difference (<jats:italic>P<\/jats:italic>\u2009=\u20090.761, 0.552, and 0.784, respectively). The results of Cox analyses revealed that there was no relationship between baseline HBV load and PFS. Additionally, HBV reactivation occurred in only 2 patients (2.9%), and no patient experienced HBV-related hepatic impairment when given a continuous TAF treatment.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Baseline HBV loads do not affect the prognosis of HCC patients receiving anti-PD-1 in combination with an antiangiogenic therapy, while PD-1 inhibitors do not aggravate HBV reactivation and hepatic impairment in patients simultaneously subjected to TAF prophylaxis.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12879-022-07602-0","type":"journal-article","created":{"date-parts":[[2022,7,14]],"date-time":"2022-07-14T12:05:14Z","timestamp":1657800314000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Interaction between baseline HBV loads and the prognosis of patients with HCC receiving anti-PD-1 in combination with antiangiogenic therapy undergoing concurrent TAF prophylaxis"],"prefix":"10.1186","volume":"22","author":[{"given":"Xiaoyun","family":"Hu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rong","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qi","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mengya","family":"Zang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guosheng","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jinzhang","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,7,14]]},"reference":[{"issue":"1","key":"7602_CR1","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1016\/j.jhep.2018.03.019","volume":"69","author":"EASL Clinical Practice Guidelines","year":"2018","unstructured":"EASL Clinical Practice Guidelines. Management of hepatocellular carcinoma. J Hepatol. 2018;69(1):182\u2013236. https:\/\/doi.org\/10.1016\/j.jhep.2018.03.019.","journal-title":"J Hepatol"},{"issue":"1","key":"7602_CR2","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1002\/hep.29086","volume":"67","author":"JK Heimbach","year":"2018","unstructured":"Heimbach JK, Kulik LM, Finn RS, et al. AASLD guidelines for the treatment of hepatocellular carcinoma. Hepatology. 2018;67(1):358\u201380. https:\/\/doi.org\/10.1002\/hep.29086.","journal-title":"Hepatology"},{"key":"7602_CR3","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21492","author":"F Bray","year":"2018","unstructured":"Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A, Global cancer statistics 2018. GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018. https:\/\/doi.org\/10.3322\/caac.21492.","journal-title":"CA Cancer J Clin"},{"key":"7602_CR4","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.00046-19","author":"MH Nguyen","year":"2020","unstructured":"Nguyen MH, Wong G, Gane E, Kao JH, Dusheiko G. Hepatitis B virus: advances in prevention, diagnosis, and therapy. Clin Microbiol Rev. 2020. https:\/\/doi.org\/10.1128\/CMR.00046-19.","journal-title":"Clin Microbiol Rev"},{"issue":"1","key":"7602_CR5","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1038\/s41575-018-0055-0","volume":"16","author":"M Wong","year":"2019","unstructured":"Wong M, Huang J, George J, et al. The changing epidemiology of liver diseases in the Asia-Pacific region. Nat Rev Gastroenterol Hepatol. 2019;16(1):57\u201373. https:\/\/doi.org\/10.1038\/s41575-018-0055-0.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"2","key":"7602_CR6","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1016\/j.jhep.2019.08.025","volume":"72","author":"AG Singal","year":"2020","unstructured":"Singal AG, Lampertico P, Nahon P. Epidemiology and surveillance for hepatocellular carcinoma: new trends. J Hepatol. 2020;72(2):250\u201361. https:\/\/doi.org\/10.1016\/j.jhep.2019.08.025.","journal-title":"J Hepatol"},{"issue":"20","key":"7602_CR7","doi-asserted-by":"publisher","first-page":"1894","DOI":"10.1056\/NEJMoa1915745","volume":"382","author":"RS Finn","year":"2020","unstructured":"Finn RS, Qin S, Ikeda M, et al. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. N Engl J Med. 2020;382(20):1894\u2013905. https:\/\/doi.org\/10.1056\/NEJMoa1915745.","journal-title":"N Engl J Med"},{"key":"7602_CR8","doi-asserted-by":"publisher","DOI":"10.1002\/hep.31306","author":"RS Finn","year":"2020","unstructured":"Finn RS, Zhu AX. Evolution of Systemic Therapy for Hepatocellular Carcinoma. Hepatology. 2020. https:\/\/doi.org\/10.1002\/hep.31306.","journal-title":"Hepatology"},{"issue":"18","key":"7602_CR9","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.21037\/atm-20-6063","volume":"8","author":"J Chen","year":"2020","unstructured":"Chen J, Hu X, Li Q, et al. Effectiveness and safety of toripalimab, camrelizumab, and sintilimab in a real-world cohort of hepatitis B virus associated hepatocellular carcinoma patients. Ann Transl Med. 2020;8(18):1187. https:\/\/doi.org\/10.21037\/atm-20-6063.","journal-title":"Ann Transl Med"},{"key":"7602_CR10","doi-asserted-by":"publisher","first-page":"12683","DOI":"10.2147\/OTT.S286169","volume":"13","author":"G Yuan","year":"2020","unstructured":"Yuan G, Cheng X, Li Q, et al. Safety and efficacy of camrelizumab combined with apatinib for advanced hepatocellular carcinoma with portal vein tumor thrombus: a multicenter retrospective study. Onco Targets Ther. 2020;13:12683\u201393. https:\/\/doi.org\/10.2147\/OTT.S286169.","journal-title":"Onco Targets Ther"},{"issue":"1","key":"7602_CR11","doi-asserted-by":"publisher","first-page":"30","DOI":"10.7326\/M15-1121","volume":"164","author":"S Paul","year":"2016","unstructured":"Paul S, Saxena A, Terrin N, Viveiros K, Balk EM, Wong JB. Hepatitis B virus reactivation and prophylaxis during solid tumor chemotherapy: a systematic review and meta-analysis. Ann Intern Med. 2016;164(1):30\u201340. https:\/\/doi.org\/10.7326\/M15-1121.","journal-title":"Ann Intern Med"},{"issue":"5","key":"7602_CR12","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2019.1581547","volume":"8","author":"C Chen","year":"2019","unstructured":"Chen C, Zhang F, Zhou N, et al. Efficacy and safety of immune checkpoint inhibitors in advanced gastric or gastroesophageal junction cancer: a systematic review and meta-analysis. Oncoimmunology. 2019;8(5): e1581547. https:\/\/doi.org\/10.1080\/2162402X.2019.1581547.","journal-title":"Oncoimmunology"},{"issue":"3","key":"7602_CR13","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1097\/CJI.0000000000000358","volume":"44","author":"EA Burns","year":"2021","unstructured":"Burns EA, Muhsen IN, Anand K, et al. Hepatitis B virus reactivation in cancer patients treated with immune checkpoint inhibitors. J Immunother. 2021;44(3):132\u20139. https:\/\/doi.org\/10.1097\/CJI.0000000000000358.","journal-title":"J Immunother"},{"issue":"1","key":"7602_CR14","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1186\/s40425-019-0808-5","volume":"7","author":"X Zhang","year":"2019","unstructured":"Zhang X, Zhou Y, Chen C, et al. Hepatitis B virus reactivation in cancer patients with positive Hepatitis B surface antigen undergoing PD-1 inhibition. J Immunother Cancer. 2019;7(1):322. https:\/\/doi.org\/10.1186\/s40425-019-0808-5.","journal-title":"J Immunother Cancer"},{"issue":"4","key":"7602_CR15","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1016\/j.jhep.2017.11.039","volume":"68","author":"K Agarwal","year":"2018","unstructured":"Agarwal K, Brunetto M, Seto WK, et al. 96weeks treatment of tenofovir alafenamide vs. tenofovir disoproxil fumarate for hepatitis B virus infection. J Hepatol. 2018;68(4):672\u201381. https:\/\/doi.org\/10.1016\/j.jhep.2017.11.039.","journal-title":"J Hepatol"},{"issue":"2","key":"7602_CR16","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1016\/j.jhep.2017.03.021","volume":"67","author":"EASL","year":"2017","unstructured":"EASL. 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. J Hepatol. 2017;67(2):370\u201398. https:\/\/doi.org\/10.1016\/j.jhep.2017.03.021.","journal-title":"J Hepatol"},{"issue":"4","key":"7602_CR17","doi-asserted-by":"publisher","first-page":"1560","DOI":"10.1002\/hep.29800","volume":"67","author":"NA Terrault","year":"2018","unstructured":"Terrault NA, Lok ASF, McMahon BJ, et al. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance. Hepatology. 2018;67(4):1560\u201399.","journal-title":"Hepatology"},{"issue":"23","key":"7602_CR18","doi-asserted-by":"publisher","first-page":"2521","DOI":"10.1001\/jama.2014.15704","volume":"312","author":"H Huang","year":"2014","unstructured":"Huang H, Li X, Zhu J, et al. Entecavir vs lamivudine for prevention of hepatitis B virus reactivation among patients with untreated diffuse large B-cell lymphoma receiving R-CHOP chemotherapy: a randomized clinical trial. JAMA. 2014;312(23):2521\u201330. https:\/\/doi.org\/10.1001\/jama.2014.15704.","journal-title":"JAMA"},{"issue":"5","key":"7602_CR19","doi-asserted-by":"publisher","first-page":"916","DOI":"10.1136\/gutjnl-2018-316510","volume":"68","author":"CJ Lim","year":"2019","unstructured":"Lim CJ, Lee YH, Pan L, et al. Multidimensional analyses reveal distinct immune microenvironment in hepatitis B virus-related hepatocellular carcinoma. Gut. 2019;68(5):916\u201327. https:\/\/doi.org\/10.1136\/gutjnl-2018-316510.","journal-title":"Gut"},{"key":"7602_CR20","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2019-000394","author":"WJ Ho","year":"2020","unstructured":"Ho WJ, Danilova L, Lim SJ, et al. Viral status, immune microenvironment and immunological response to checkpoint inhibitors in hepatocellular carcinoma. J Immunother Cancer. 2020. https:\/\/doi.org\/10.1136\/jitc-2019-000394.","journal-title":"J Immunother Cancer"},{"key":"7602_CR21","doi-asserted-by":"publisher","DOI":"10.1016\/j.gene.2021.145935","volume":"806","author":"HN Xuan","year":"2022","unstructured":"Xuan HN, Thi MHP, Dinh TB, et al. Association of PD-L1 gene polymorphisms and circulating sPD-L1 levels with HBV infection susceptibility and related liver disease progression. Gene. 2022;806: 145935. https:\/\/doi.org\/10.1016\/j.gene.2021.145935.","journal-title":"Gene"},{"issue":"4","key":"7602_CR22","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1158\/1078-0432.CCR-20-2571","volume":"27","author":"J Xu","year":"2021","unstructured":"Xu J, Shen J, Gu S, et al. Camrelizumab in combination with apatinib in patients with advanced hepatocellular carcinoma (RESCUE): a nonrandomized, open-label. Phase II Trial Clin Cancer Res. 2021;27(4):1003\u201311. https:\/\/doi.org\/10.1158\/1078-0432.CCR-20-2571.","journal-title":"Phase II Trial Clin Cancer Res"},{"issue":"3","key":"7602_CR23","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1159\/000505695","volume":"9","author":"H Deng","year":"2020","unstructured":"Deng H, Kan A, Lyu N, et al. Dual vascular endothelial growth factor receptor and fibroblast growth factor receptor inhibition elicits antitumor immunity and enhances programmed cell death-1 checkpoint blockade in hepatocellular carcinoma. Liver Cancer. 2020;9(3):338\u201357. https:\/\/doi.org\/10.1159\/000505695.","journal-title":"Liver Cancer"},{"issue":"3","key":"7602_CR24","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1111\/sji.12524","volume":"85","author":"N Trehanpati","year":"2017","unstructured":"Trehanpati N, Vyas AK. Immune regulation by T regulatory cells in hepatitis B virus-related inflammation and cancer. Scand J Immunol. 2017;85(3):175\u201381. https:\/\/doi.org\/10.1111\/sji.12524.","journal-title":"Scand J Immunol"},{"issue":"6","key":"7602_CR25","doi-asserted-by":"publisher","first-page":"1297","DOI":"10.1053\/j.gastro.2017.02.009","volume":"152","author":"R Loomba","year":"2017","unstructured":"Loomba R, Liang TJ. Hepatitis B reactivation associated with immune suppressive and biological modifier therapies: current concepts, management strategies, and future directions. Gastroenterology. 2017;152(6):1297\u2013309. https:\/\/doi.org\/10.1053\/j.gastro.2017.02.009.","journal-title":"Gastroenterology"},{"issue":"10088","key":"7602_CR26","doi-asserted-by":"publisher","first-page":"2492","DOI":"10.1016\/S0140-6736(17)31046-2","volume":"389","author":"AB El-Khoueiry","year":"2017","unstructured":"El-Khoueiry AB, Sangro B, Yau T, et al. Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1\/2 dose escalation and expansion trial. Lancet. 2017;389(10088):2492\u2013502. https:\/\/doi.org\/10.1016\/S0140-6736(17)31046-2.","journal-title":"Lancet"},{"issue":"7","key":"7602_CR27","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1016\/S1470-2045(18)30351-6","volume":"19","author":"AX Zhu","year":"2018","unstructured":"Zhu AX, Finn RS, Edeline J, et al. Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial. Lancet Oncol. 2018;19(7):940\u201352. https:\/\/doi.org\/10.1016\/S1470-2045(18)30351-6.","journal-title":"Lancet Oncol"},{"key":"7602_CR28","doi-asserted-by":"publisher","first-page":"337","DOI":"10.2147\/JHC.S278527","volume":"7","author":"X Sun","year":"2020","unstructured":"Sun X, Hu D, Yang Z, et al. Baseline HBV loads do not affect the prognosis of patients with hepatocellular carcinoma receiving anti-programmed cell death-1 immunotherapy. J Hepatocell Carcinoma. 2020;7:337\u201345. https:\/\/doi.org\/10.2147\/JHC.S278527.","journal-title":"J Hepatocell Carcinoma"},{"issue":"5","key":"7602_CR29","doi-asserted-by":"publisher","first-page":"900","DOI":"10.1016\/j.jhep.2019.06.028","volume":"71","author":"E Gane","year":"2019","unstructured":"Gane E, Verdon DJ, Brooks AE, et al. Anti-PD-1 blockade with nivolumab with and without therapeutic vaccination for virally suppressed chronic hepatitis B: a pilot study. J Hepatol. 2019;71(5):900\u20137. https:\/\/doi.org\/10.1016\/j.jhep.2019.06.028.","journal-title":"J Hepatol"},{"key":"7602_CR30","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-021-02911-w","author":"MK He","year":"2021","unstructured":"He MK, Peng C, Zhao Y, et al. Comparison of HBV reactivation between patients with high HBV-DNA and low HBV-DNA loads undergoing PD-1 inhibitor and concurrent antiviral prophylaxis. Cancer Immunol Immunother. 2021. https:\/\/doi.org\/10.1007\/s00262-021-02911-w.","journal-title":"Cancer Immunol Immunother"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-022-07602-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12879-022-07602-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-022-07602-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,14]],"date-time":"2022-07-14T12:09:18Z","timestamp":1657800558000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcinfectdis.biomedcentral.com\/articles\/10.1186\/s12879-022-07602-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,14]]},"references-count":30,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["7602"],"URL":"https:\/\/doi.org\/10.1186\/s12879-022-07602-0","relation":{},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,14]]},"assertion":[{"value":"21 April 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 July 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 July 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors are accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved. All procedures performed in this study involving human participants were in accordance with the 1975 Declaration of Helsinki. The Ethical Committee of Nanfang Hospital, Southern Medical University granted approval for this study, and written informed consent was obtained from each patient before the procedure.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors have no conflicts of interest to disclose.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"614"}}